Anthera Pharmaceuticals , Nasdaq: ANTH
Developing anti-inflammatory therapies for acute coronary syndrome and lupus.
Industry: Health Care
First Day Return: +0.1%
Industry: Health Care
| IPO Data | |
|---|---|
| IPO File Date | 09/16/2009 |
| Offer Price | $7.00 |
| Price Range $13.00 - $15.00 | |
| Offer Shares (mm) | 6.0 |
| Deal Size ($mm) | $42 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 02/28/2010 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $42 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Hayward, CA, United States |
| Founded | 2004 |
| Employees at IPO | n/a |
| Website www.anthera.com | |
Anthera Pharmaceuticals (ANTH) Performance
